Trivalent Inactivated Influenza Virus Vaccine Given to Two-Month-Old Children
Authors:
- Emmanuel B. WalterEWEmmanuel B. Walter
- Janet A. EnglundJEJanet A. Englund
- Mark BlatterMBMark Blatter
- Jack NybergJNJack Nyberg
- Frederick L. RubenFRFrederick L. Ruben
- Michael D. DeckerMDMichael D. Decker
- 1 December 2009
- journal article
- clinical trial
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 28 (12) , 1099-1104
Abstract
Although children less than 6 months of age have the highest risk for hospitalization related to influenza infection, influenza vaccine is not approved for these children. In an open-label, off-season study, healthy 6 to 12 week and 6-month-old children received 2 doses of the 2004 to 2005 trivalent inactivated influenza vaccine (TIV) administered 1 month apart along with other routine pediatric vaccines. Safety was assessed by parental diaries (n = 393). Immunogenicity analyses (n = 293) were performed on sera obtained before vaccination and 1 month after the second dose of TIV. Outcomes included the frequencies of subjects with injection site and systemic reactions and seroprotection rates to TIV antigens. Injection site reactions and fevers were generally mild and resolved within 3 days. Postvaccination seroprotection rates (titer > or = 1:40) in the 6- to 12-week-old and 6-month-old groups were 46% and 69% to A/New Caledonia (H1N1), 59% and 79% to A/Wyoming (H3N2), and 5% and 22% to B/Jiangsu (P < 0.001, all comparisons). For seronegative 6- to 12-week-olds whose mothers had not received TIV during pregnancy, postvaccination seroprotective titers to A/New Caledonia (H1N1) were achieved in 70% (38/54) and to A/Wyoming (H3N2) in 68% (23/34) of infants. TIV was well tolerated and safe when administered to children at both 6 to 12 weeks and 6 months of age. The antibody response was lower in the younger children, probably related to antibody suppression from passively acquired antibodies from mothers. In 6- to 12-week-olds without preexisting antibody, seroresponses to influenza A antigens approached those of 6-month-old children.Keywords
This publication has 23 references indexed in Scilit:
- Safety and Immunogenicity of Trivalent Inactivated Influenza Vaccine in InfantsThe Journal of Infectious Diseases, 2008
- Immunogenicity and Reactogenicity of 1 versus 2 Doses of Trivalent Inactivated Influenza Vaccine in Vaccine‐Naive 5–8‐Year‐Old ChildrenThe Journal of Infectious Diseases, 2006
- Immunization With Trivalent Inactivated Influenza Vaccine in Partially Immunized ToddlersPediatrics, 2006
- Influenza Vaccine Immunogenicity in 6- to 23-Month-Old Children: Are Identical Antigens Necessary for Priming?Pediatrics, 2006
- Influenza-Associated Hospitalizations in the United StatesJAMA, 2004
- Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infantsThe Journal of Pediatrics, 2004
- Studies of the 1996–1997 Inactivated Influenza Vaccine among Children Attending Day Care: Immunologic Response, Protection against Infection, and Clinical EffectivenessThe Journal of Infectious Diseases, 2000
- The Effect of Influenza on Hospitalizations, Outpatient Visits, and Courses of Antibiotics in ChildrenNew England Journal of Medicine, 2000
- Studies on reactogenicity and immunogenicity of attenuated bivalent cold recombinant influenza type A (CRA) and inactivated trivalent influenza virus (TI) vaccines in infants and young childrenVaccine, 1993
- Natural or vaccine-induced antibody as a predictor of immunity in the face of natural challenge with influenza virusesEpidemiology and Infection, 1989